More than 15 million US adults have ADHD, new study estimates
By Puyaan Singh
Oct 10 (Reuters) -Roughly 15.5 million U.S. adults have attention-deficit hyperactivity disorder, and most of them struggle with gaining access to treatment for the condition, according to data from a U.S. study released on Thursday.
Only about one-third of those reporting a diagnosis of ADHD said they had received a prescription for a stimulant drug used to treat it in the previous year, researchers reported in the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
In addition, nearly three quarters of those with a prescription for a stimulant drug reported difficulty getting it filled because the medication was unavailable.
Worldwide, around 2% to 5% of adults experience ADHD symptoms such as inattention, hyperactivity, and impulsivity. This study provides the first prevalence data on ADHD in U.S. adults since 2003.
The amphetamine drug, commonly sold under the brand name Adderall, is a first-line, or initial option, treatment for adults with ADHD.
Prescribing has increased since the COVID-19 pandemic began, but shortages of this and other stimulant medications have affected patients who rely on it, the study found.
ADHD symptoms typically begin in childhood. In the survey, however, 55% of those with the condition said they had been diagnosed as adults.
Telehealth policies implemented during the COVID-19 pandemic expanded access to ADHD diagnosis and treatment, including medication, the researchers from the CDC noted in the report.
Almost half of surveyed individuals had turned to telehealth services for ADHD-related care, including for access to medication.
The survey's findings could help guide clinical care and regulatory decisions, including around prescribing through telemedicine, its authors said.
Telemedicine might improve access to behavioral treatment, such as counseling or therapy, as well as for medication prescriptions, for these patients, they said, although research into the effectiveness and safety of telemedicine for ADHD is limited.
The study's estimates are based on National Center for Health Statistics rapid survey data collected during October–November 2023 from 7,046 adults age 18 or older.
Reporting by Puyaan Singh in Bengaluru; editing by Nancy Lapid and Bill Berkrot
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
